Skip to main content

VLDLR KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.

Be the first to review this product! Submit a review

Images

Next Generation Sequencing - Human VLDLR knockout U-87 MG cell line (AB306807), expandable thumbnail

Key facts

Cell type
U-87 MG
Species or organism
Human
Tissue
Brain
Form
Liquid
Knockout validation
Next Generation Sequencing

Recommended products

VLDLR KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.

Key facts

Cell type
U-87 MG
Form
Liquid
Disease
Glioblastoma
Concentration
Loading...

Properties

Gene name
VLDLR
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing

Cell culture

Biosafety level
EU: 1 US: 1
Viability
~ 80%
Adherent/suspension
Adherent
Gender
Male

Handling procedures

Initial handling guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
EMEM + 10% FBS

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.

Recommended control: Human wild-type U-87 MG cell line (ab278079). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

Cryopreservation cell medium: Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Culture medium:  EMEM + 10% FBS  

Initial handling guidelines: Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.

2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.

3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25. 

4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. 

5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines:

• All seeding densities should be based on cell counts gained by established methods.

• A guide seeding density of 2x104 cells/cm2 is recommended.

• Cells should be passaged when they have achieved 80-90% confluence.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The VLDL Receptor also known as VLDL-R mediates the uptake of very low-density lipoproteins (VLDLs) into cells. This receptor has a molecular mass of approximately 104 kDa. It is structurally similar to the low-density lipoprotein (LDL) receptor and binds to apolipoprotein E-containing lipoproteins. VLDL-R expresses in several tissues including heart skeletal muscle and adipose tissue. Its distribution suggests an important role in lipid metabolism for energy production and storage.

Biological function summary

VLDL-R significantly influences lipid and lipoprotein metabolism by facilitating the endocytosis of triglyceride-rich particles. It functions within the larger receptor family known as the LDL receptor family. VLDL-R plays an important role in cellular lipid uptake and the subsequent supply of fatty acids which are necessary for various metabolic processes. This receptor does not function as part of a protein complex but its interactions with other proteins can alter its activity and the cell's metabolic state.

Pathways

This receptor influences lipid metabolism and energy homeostasis pathways. It directly impacts the lipid biosynthetic pathway by mediating the cellular uptake of lipid components necessary for these processes. The receptor interacts with proteins like apolipoprotein B and E which regulate lipoprotein assembly and clearance. In this pathway VLDL-R works conjunctionally with the LDL receptor to maintain lipid balance within the body.

Associated diseases and disorders

VLDL-R relates to metabolic syndrome and obesity. Abnormalities in VLDL-R function can lead to dyslipidemia a risk factor for these conditions due to the mishandling of lipid uptake. This association connects VLDL-R to apolipoprotein E and B whose mutations can also contribute to these metabolic disorders. Understanding how VLDL-R operates in these contexts may provide insight into therapeutic targets for these widespread health issues.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • Next Generation Sequencing - Human VLDLR knockout U-87 MG cell line (ab306807), expandable thumbnail

    Next Generation Sequencing - Human VLDLR knockout U-87 MG cell line (ab306807)

    172 bp deletion after Asn99 of the WT protein

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com